Needham Initiates Coverage On AppLovin with Hold Rating

Needham analyst Bernie McTernan initiates coverage on AppLovin (NASDAQ:APP) with a Hold rating.

byBenzinga Newsdesk

October 7, 2022

1 minute read

Needham analyst Bernie McTernan initiates coverage on AppLovin (NASDAQ:APP) with a Hold rating.

Hillenbrand Names Robert VanHimbergen As Finance Chief

By Akanksha Bakshi

March 10, 2:06 PM

Hillenbrand, Inc. (NYSE:HI) has selected Robert VanHimbergen to join the company as Executive Vice President, Finance, on March 14 and assume…

News

Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview

By Benzinga Newsdesk

August 16, 7:18 AM

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Chairman and CEO, Greg Duncan,

VIRI

Outbrain Q2 EPS $0.28 Up From $(0.16) YoY, Sales $247.00M Up From $157.90M YoY

By Bill Haddad

August 17, 6:41 AM

Outbrain (NASDAQ:OB) reported quarterly earnings of $0.28 per share. This is a 275 percent increase over losses of $(0.16) per share from the same period last year. The company reported $247.00 million in sales this

Integral Ad Science Q2 EPS $(0.26) Misses $(0.03) Estimate, Sales $75.10M Beat $70.55M Estimate

By Bill Haddad

August 12, 4:43 PM

Integral Ad Science (NASDAQ:IAS) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.03) by 766.67 percent. The company reported quarterly sales of $75.10 million which beat

IAS

Needham Initiates Coverage On AppLovin with Hold Rating

Related Posts

Hillenbrand Names Robert VanHimbergen As Finance Chief

Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview

Outbrain Q2 EPS $0.28 Up From $(0.16) YoY, Sales $247.00M Up From $157.90M YoY

Integral Ad Science Q2 EPS $(0.26) Misses $(0.03) Estimate, Sales $75.10M Beat $70.55M Estimate